CBR-2092
| Code | Size | Price |
|---|
| TAR-T26963-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
CBR-2092 is a DNA-directed RNA polymerase and DNA topoisomerase inhibitor. CBR-2092 exhibited rifampin-like potency as an inhibitor of RNA polymerase, was an equipotent (balanced) inhibitor of DNA gyrase and DNA topoisomerase IV, and retained activity against a prevalent quinolone-resistant variant. Studies of mutant strains that exhibited reduced susceptibility to CBR-2092 further substantiated RNA polymerase as the primary cellular target of CBR-2092, with DNA gyrase and DNA topoisomerase IV being secondary and tertiary targets, respectively, in strains exhibiting preexisting rifampin resistance.
CAS:
922717-97-3
Formula:
C65H81FN6O15
Molecular Weight:
1205.388
Purity:
0.98
SMILES:
CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCC(CC4)N(C)C4(CC4)[C@@H]4CCN(C4)c4c(F)cn5c(c4C)c(cc(C(O)=O)c5=O)C4CC4)c(NC(=O)C(C)=C/C=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C
References
1. Karpiuk I, Tyski S. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials. Przegl Epidemiol. 2013;67(3):455-60, 557-61. English, Polish. PubMed PMID: 24340560.
2. Prathipati P, Ma NL, Manjunatha UH, Bender A. Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. J Proteome Res. 2009 Jun;8(6):2788-98. doi: 10.1021/pr8010843. PubMed PMID: 19301903.
3. Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Jul;52(7):2313-23. doi: 10.1128/AAC.01649-07. PubMed PMID: 18443108; PubMed Central PMCID: PMC2443886.
4. Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother. 2008 Jul;52(7):2324-34. doi: 10.1128/AAC.01651-07. PubMed PMID: 18443106; PubMed Central PMCID: PMC2443883.